These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 12034146)

  • 1. Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis.
    Gharib MI; Burnett AK
    Eur J Heart Fail; 2002 Jun; 4(3):235-42. PubMed ID: 12034146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention.
    Pai VB; Nahata MC
    Drug Saf; 2000 Apr; 22(4):263-302. PubMed ID: 10789823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiotoxicity of chemotherapy.
    de Forni M; Armand JP
    Curr Opin Oncol; 1994 Jul; 6(4):340-4. PubMed ID: 7803534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Chemotherapy-induced cardiotoxicity: Incidence, diagnosis and prevention].
    Nelson-Veniard M; Thambo JB
    Bull Cancer; 2015; 102(7-8):622-6. PubMed ID: 25935231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiotoxicity of cancer chemotherapy: implications for children.
    Simbre VC; Duffy SA; Dadlani GH; Miller TL; Lipshultz SE
    Paediatr Drugs; 2005; 7(3):187-202. PubMed ID: 15977964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiotoxicity of doxorubicin and other anthracycline derivatives.
    Jain D
    J Nucl Cardiol; 2000; 7(1):53-62. PubMed ID: 10698235
    [No Abstract]   [Full Text] [Related]  

  • 7. Natriuretic peptides: biochemical markers of anthracycline cardiac toxicity?
    Urbanova D; Urban L; Danova K; Simkova I
    Oncol Res; 2008; 17(2):51-8. PubMed ID: 18543606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Chemotherapy and cardiotoxicity].
    Brestescher C; Pautier P; Farge D
    Ann Cardiol Angeiol (Paris); 1995 Oct; 44(8):443-7. PubMed ID: 8669796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity.
    Chung WB; Youn HJ
    Korean J Intern Med; 2016 Jul; 31(4):625-33. PubMed ID: 27378126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-induced Cardiotoxicity.
    Nabati M; Janbabai G; Baghyari S; Esmaili K; Yazdani J
    J Cardiovasc Pharmacol; 2017 May; 69(5):279-285. PubMed ID: 28141699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cardiotoxicity of drugs used in oncology].
    Poprach A; Petráková K; Vyskocil J; Lakomý R; Nemecek R; Kocák I; Kocáková I; Vyzula R
    Klin Onkol; 2008; 21(5):288-93. PubMed ID: 19202960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cardiologic sequelae of cytostatic therapy].
    Mladosievivcová B
    Cas Lek Cesk; 2001 Mar; 140(5):138-41. PubMed ID: 11347200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical markers for prediction of chemotherapy-induced cardiotoxicity: systematic review of the literature and recommendations for use.
    Dolci A; Dominici R; Cardinale D; Sandri MT; Panteghini M
    Am J Clin Pathol; 2008 Nov; 130(5):688-95. PubMed ID: 18854260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarkers for the early detection of anthracycline-induced cardiotoxicity: current status.
    Horacek JM; Vasatova M; Pudil R; Tichy M; Zak P; Jakl M; Jebavy L; Maly J
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2014 Dec; 158(4):511-7. PubMed ID: 24457832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities.
    Vejpongsa P; Yeh ET
    J Am Coll Cardiol; 2014 Sep; 64(9):938-45. PubMed ID: 25169180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategies for prevention of anthracycline cardiotoxicity.
    Basser RL; Green MD
    Cancer Treat Rev; 1993 Jan; 19(1):57-77. PubMed ID: 8431927
    [No Abstract]   [Full Text] [Related]  

  • 17. Anthracycline-induced cardiotoxicity.
    Hrdina R; Gersl V; Klimtová I; Simůnek T; Machácková J; Adamcová M
    Acta Medica (Hradec Kralove); 2000; 43(3):75-82. PubMed ID: 11089274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathophysiology of cardiotoxicity induced by nonanthracycline chemotherapy.
    Madeddu C; Deidda M; Piras A; Cadeddu C; Demurtas L; Puzzoni M; Piscopo G; Scartozzi M; Mercuro G
    J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e12-e18. PubMed ID: 27755238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of biomarkers in chemotherapy-induced cardiotoxicity.
    Cardinale D; Sandri MT
    Prog Cardiovasc Dis; 2010; 53(2):121-9. PubMed ID: 20728699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utilizing cardiac biomarkers to detect and prevent chemotherapy-induced cardiomyopathy.
    Singh D; Thakur A; Tang WH
    Curr Heart Fail Rep; 2015 Jun; 12(3):255-62. PubMed ID: 25869733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.